Visual Outcome after Treatment with Low-Dose Recombinant Tissue Plasminogen Activator or Hemodilution in Ischemic Central Retinal Vein Occlusion

Publisher： Karger

E-ISSN： 1423-0267|213|6|360-366

ISSN： 0030-3755

Source： Ophthalmologica, Vol.213, Iss.6, 1999-11, pp. : 360-366

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fibrinolytic Therapy with Low-Dose Recombinant Tissue Plasminogen Activator in Retinal Vein Occlusion

By  

Ophthalmologica, Vol. 212, Iss. 6, 1998-09 ,pp. : 394-398

Karger

Access to resources Recommend Favorite

Impact of Intravitreal Injection of Tissue Plasminogen Activator on Full-Field Electroretinogram in Patients with Macular Oedema Secondary to Retinal Vein Occlusion

By  

Ophthalmologica, Vol. 226, Iss. 2, 2011-05 ,pp. : 81-86

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

By  

Ophthalmologica, Vol. 233, Iss. 1, 2014-12 ,pp. : 8-17

Karger

Access to resources Recommend Favorite

Intravitreal Functional Plasminogen Is Elevated in Central Retinal Vein Occlusion

By  

Ophthalmic Research, Vol. 50, Iss. 3, 2013-08 ,pp. : 151-159

Karger

Access to resources Recommend Favorite

Intravitreal Bevacizumab for Macular Edema Due to Central Retinal Vein Occlusion: Perfused vs. Ischemic and Early vs. Late Treatment

By DeCroos Francis Char   Ehlers Justis P.   Stinnett Sandra   Fekrat Sharon  

Current Eye Research, Vol. 36, Iss. 12, 2011-12 ,pp. : 1164-1170

Informa Healthcare

Access to resources Recommend Favorite